|
|
|
| Effect of hyperthermia combined with intracavitary infusion chemotherapy on abdominal cancer with malignant pleural effusion and ascites |
| HUANG Hansheng YANG Xiaomei FU Junmin CHEN Chaoting WEN Jianmei MO Qia |
| Medical Oncology Department, the Second Affiliated Hospital of Guangxi University of Science and Technology, Guangxi Zhuang Autonomous Region, Liuzhou 545006, China |
|
|
|
Abstract Objective To investigate the clinical efficacy of hyperthermia combined with intracavitary infusion chemotherapy on abdominal cancer with malignant pleural effusion and ascites and its influence on tumor markers in serum and pleural effusion and ascites. Methods From January 2017 to May 2018, 80 cases of patients with abdominal cancer and malignant pleural effusion admitted to the Second Affiliated Hospital of Guangxi University of Science and Technology were selected. The patients were divided into control group (n = 40) and study group (n = 40) according to the random number table method. Patients in the control group were treated with intravitreal chemotherapy, and patients in the study group were treated with hyperthermia combined with intravitreal chemotherapy. Patients in the two groups were treated for 4 weeks continuously, and the short-term effects of the two groups were evaluated and compared. Serum (CEA), saccharide antigen 19-9 (CA19-9), saccharide antigen 12-5 (CA12-5) and cytokeratin 19 fragment (CYFRA21-1) of the two groups were measured before and after treatment, respectively, and toxic and adverse reactions of the two groups were observed. Results The total effective rate of the study group was higher than that of the control group (P ＜ 0.01). Compared with before treatment, CEA, CA19-9, CA12-5 and CYFRA21-1 levels in serum and hydrothorax of the two groups were significantly reduced after treatment (P ＜ 0.05), and the levels in the study group were lower than those in the control group (P ＜ 0.05). No serious adverse reactions occurred during the treatment in both groups. Conclusion The short-term effect of hyperthermia combined with intravitary perfusion chemotherapy in the treatment of abdominal cancer with malignant pleural effusion is significant, which can significantly reduce the level of relevant tumor markers in serum and pleural effusion, and has a good safety.
|
|
|
|
|
|
[1] 刘晓霞，武金宝.临床腹水发病机制研究进展[J].智慧健康，2017，3（2）：37-39.
[2] 肖永生，梁志鹏，何海洋.中西医结合治疗恶性胸腹水疗效分析[J].内蒙古中医药，2017，36（13）：57-58.
[3] 姚娟，李彦磊，姜玉华，等.复方苦参注射液联合顺铂治疗恶性胸腹水疗效观察[J].辽宁中医杂志，2018，45（3）：563-564.
[4] 周云凤，廖新民，刘洋，等.深部热疗联合腔内灌注化疗对恶性胸腹水患者疗效及生活质量的影响[J].肿瘤药学，2017，7（4）：421-424，435.
[5] 周济昌.实用肿瘤内科学[M].2版.北京：人民卫生出版社，2003，45-46.
[6] 周琴.华蟾素注射液胸腹腔灌注治疗恶性胸腹腔积液的临床研究[D].北京：北京中医药大学，2012.
[7] 李枋霏，王维，张仲妍，等.葶苈大枣泻肺汤辅助化疗治疗肺癌恶性胸腔积液临床研究[J].国际中医中药杂志，2018，40（3）：214-217.
[8] 马晓娟，张旭，江泳.111例腹水病因分析[J].临床荟萃，2016，31（2）：211-213，217.
[9] 安芝，徐杨.腹腔镜检查在不明原因腹水诊断中的作用[J].临床与病理杂志，2015，35（9）：1701-1705.
[10] 廖巧芳，邓卓娟，冯韵恬，等.顺铂联合重组人血管内皮抑制素治疗结直肠癌恶性腹水近期疗效观察[J].内科，2018，13（6）：895-896.
[11] 王琴.热灌注治疗10例癌性胸腹水的护理研究[J].实用临床护理学电子杂志，2019，4（1）：120.
[12] 杜国波，蒋琳，周晶，等.洛铂联合恩度腔内灌注加深部热疗治疗恶性胸腔积液的临床观察[J].中国癌症防治杂志，2017，9（2）：152-154.
[13] 彭楠，赵彼德.临床肿瘤热疗学[M].北京：人民军医出版社，2003：50-98.
[14] 刘会芝，吕雅蕾.体外高频热疗联合顺铂腔内灌注化疗对恶性胸腹水患者的疗效观察[J].河北医药，2009，31（2）：207.
[15] 刘平，胡春宏，刘先领，等.腔内灌注化疗联合全身热疗治疗恶性胸腔积液的疗效[J].医学临床研究，2007，24（6）：978-979.
[16] 刘超群，沈刚，胡焉凡，等.细胞形态计量学联合肿瘤标志物检测对恶性胸腹水诊断价值的探讨[J].中国卫生检验杂志，2018，28（11）：1338-1340.
[17] 谭丽珊.液基细胞学联合CEA、CA199、KI-67检测在胸腹水恶性肿瘤中的表达[J].中国社区医师：医学专业，2013，15（9）：278-279.
[18] 李敬萍，凌敏.联合检测IL-16与CA125在结核性胸膜炎中的表达及意义[J].中华临床医师杂志：电子版，2015， 9（13）：2513-2515.
[19] 李汝芳，张剑青，王旭明，等.α-烯醇化酶联合CYFRA21-1、CA125在恶性胸腔积液诊断中的应用[J].实用医学杂志，2017，33（18）：3114-3118.
[20] 刘先领，马芳，胡春宏，等.腔内灌注化疗联合全身热疗治疗恶性胸腹腔积液临床研究[J].中国现代医学杂志，2006，16（6）：939-940，942.
[21] 朱泽浩，周挺，王辉.可弯曲内科胸腔镜联合肿瘤标志物诊断恶性胸腔积液的价值分析[J].中国现代医生，2017，55（2）：79-82. |
|
|
|
